Live Breaking News & Updates on Secures global rights

Stay informed with the latest breaking news from Secures global rights on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Secures global rights and stay connected to the pulse of your community

KemPharm Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On Trevyent

(2)
NEW YORK CITY (dpa-AFX) - Today's Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizer's Lorbrena, United Therapeutics scrapping the development of Trevyent, Vir Biotechnology closing the enrollment in VIR-7831 arm of ACTIV-3 trial, and Takeda securing global rights to Ovid's investigational medicine Soticlestat.
Read on.
1.KemPharm Scores FDA Nod For ADHD Drug
KemPharm Inc. (KMPH) soared more than 42% on Wednesday, following FDA approval of AZSTARYS (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older.

India , Japan , Bharat , Takeda-shonan , Johnson-concerta , Ovid-soticlestat , Vir-biotechnology-inc , Glaxosmithkline , Magenta-therapeutics-inc , Corium-inc , Ocugen-inc , Pfizer

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Amgen Inc. (NASDAQ:AMGN) - The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Amgen Inc. (NASDAQ:AMGN) - The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Boston , Massachusetts , United-states , United-kingdom , American , Strongbridge-biopharma , Boston-scientific-corporation , Glaxosmithkline , Takeda-pharmaceutical-company-limited , Medicinova-to-discontinue-development , Maravai-lifesciences-holdings-inc , Exicure-inc